From BigGo Finance · BigGo Finance · · 3m
Oral Hair-Loss Drug Aces Phase 3 Trial
Veradermics oral hair-loss drug VDPHL01 meets Phase 3 trial targets, sparking 11% stock surge.
In brief
Veradermics oral hair-loss drug VDPHL01 meets Phase 3 trial targets, sparking 11% stock surge. Veradermics' oral hair-loss drug VDPHL01 achieved key Phase 3 trial results, potentially becoming the first FDA-approved non-hormonal oral treatment for hair loss in nearly 30 years. Originally reported by BigGo Finance.
Veradermics Announces Phase 3 Success
U.S. biopharmaceutical company Veradermics announced its extended-release oral minoxidil formulation VDPHL01 met all primary and secondary endpoints in Part A of its registrational Phase 3 study, Study 304.
Trial Results Show Strong Hair Growth
The trial enrolled 536 men with mild-to-moderate androgenetic alopecia; after six months, the once-daily and twice-daily groups showed mean increases of 28.6 and 36.
Patient Self-Assessment Improves
The proportion of patients self-reporting 'improved' or 'greatly improved' was 55.7% and 68.7%, respectively, versus 15.0% for placebo.
Drug Well Tolerated
The drug was generally well tolerated, with no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
Stock Surges 11% Intraday
The news sent the stock up more than 11% intraday, with Veradermics shares trading at NYSE: MANE.
Potential First FDA Approval
The company says the drug could become the first FDA-approved non-hormonal oral treatment for androgenetic alopecia in nearly 30 years.
Competitive Landscape
Cosmo, Pelage, and Eli Lilly-backed Amplifica and Absci are all pursuing this cash-pay medical market.
Market Potential
Pharmaceutical companies and investors generally believe hair-loss treatment could grow into a lucrative cash-pay medical market, following a path similar to the rapidly expanding weight-loss drug market in recent years.
Investor Expert Opinion
Jared Holz, a healthcare industry expert at Mizuho Securities, believes hair loss could become the next large consumer medical market, saying competition in the field is 'getting fiercer by the day.'
Japanese Market Differences
The Japanese Dermatological Association lists topical minoxidil as Recommendation Grade A but oral minoxidil as Grade D, citing systemic side effect risks.
Market Impact Potential
If VDPHL01 is approved, it could create an opening in brand awareness and prescribing habits and drive the entire category toward oral, extended-release, low-cardiac-risk options.
Next Steps for Approval
Veradermics has not yet conducted a head-to-head comparison with conventional oral minoxidil, so the drug's real-world advantage remains uncertain.
Competitor Developments
Cosmo Pharmaceuticals has produced positive results in two Phase 3 trials with 1,465 patients; Pelage Pharmaceuticals has enrolled its first patient in a Phase 2/3 trial.
Market Access Timeline
Key factors for market success include FDA review timeline, pricing, efficacy comparison data versus generic minoxidil, and launch cadence of competitors.
The short version
Veradermics' oral hair-loss drug VDPHL01 achieved key Phase 3 trial results, potentially becoming the first FDA-approved non-hormonal oral treatment for hair loss in nearly 30 years.
